Fate Therapeutics starts Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, with Phase 1 promise and pipeline updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results